XY Capital Ltd Has $1.43 Million Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• XY Capital Ltd reduced its stake in Takeda Pharmaceutical by 41.1%, now holding 95,830 shares valued at approximately $1.43 million.
• Takeda's most recent earnings report showed an EPS of $0.52, exceeding analysts' estimates of $0.47, despite quarterly revenue of $7.45 billion falling short of estimates.
• The company's stock is currently trading at $14.39, with a market capitalization of $45.77 billion and a P/E ratio of 47.95.

XY Capital Ltd decreased its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 41.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,830 shares of the company's stock after selling 66,872 shares during the period. Takeda Pharmaceutical comprises 0.4% of XY Capital Ltd's holdings, making the stock its 21st largest holding. XY Capital Ltd's holdings in Takeda Pharmaceutical were worth $1,425,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. First Trust Advisors LP grew its holdings in shares of Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock valued at $42,910,000 after purchasing an additional 62,718 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock worth $24,806,000 after buying an additional 238,161 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Takeda Pharmaceutical by 136.0% in the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock valued at $15,623,000 after acquiring an additional 680,000 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Takeda Pharmaceutical by 24.6% during the 1st quarter. Federated Hermes Inc. now owns 541,919 shares of the company's stock valued at $8,058,000 after acquiring an additional 106,885 shares in the last quarter. Finally, Toronto Dominion Bank acquired a new position in Takeda Pharmaceutical in the 4th quarter worth about $6,760,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $14.39 on Friday. The firm has a market capitalization of $45.77 billion, a price-to-earnings ratio of 47.95 and a beta of 0.22. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. The business's 50-day moving average price is $14.83 and its 200-day moving average price is $14.55. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.